JP2014511395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511395A5 JP2014511395A5 JP2013557866A JP2013557866A JP2014511395A5 JP 2014511395 A5 JP2014511395 A5 JP 2014511395A5 JP 2013557866 A JP2013557866 A JP 2013557866A JP 2013557866 A JP2013557866 A JP 2013557866A JP 2014511395 A5 JP2014511395 A5 JP 2014511395A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- membered
- nhc
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 242
- 229910052757 nitrogen Inorganic materials 0.000 claims description 192
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 160
- 229910052760 oxygen Inorganic materials 0.000 claims description 160
- 239000001301 oxygen Chemical group 0.000 claims description 160
- 229920006395 saturated elastomer Polymers 0.000 claims description 149
- 150000001875 compounds Chemical class 0.000 claims description 147
- 125000005842 heteroatom Chemical group 0.000 claims description 145
- 229910052717 sulfur Chemical group 0.000 claims description 143
- 239000011593 sulfur Chemical group 0.000 claims description 141
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 140
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 116
- 101150065749 Churc1 gene Proteins 0.000 claims description 116
- 102100038239 Protein Churchill Human genes 0.000 claims description 116
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 98
- 229910052736 halogen Inorganic materials 0.000 claims description 92
- 150000002367 halogens Chemical class 0.000 claims description 92
- 125000001931 aliphatic group Chemical group 0.000 claims description 78
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- 239000001257 hydrogen Substances 0.000 claims description 62
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 125000002619 bicyclic group Chemical group 0.000 claims description 41
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- -1 aminopyrimidinyl Chemical group 0.000 claims description 21
- 150000002431 hydrogen Chemical group 0.000 claims description 21
- 125000002950 monocyclic group Chemical group 0.000 claims description 20
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 19
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 18
- 125000002757 morpholinyl group Chemical group 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 7
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims description 6
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 6
- 239000003607 modifier Substances 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 241000721454 Pemphigus Species 0.000 claims description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 4
- 230000009826 neoplastic cell growth Effects 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 206010001889 Alveolitis Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000017701 Endocrine disease Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 206010049466 Erythroblastosis Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 241000370541 Idia Species 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 2
- 206010029350 Neurotoxicity Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 201000004571 bone carcinoma Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 201000002758 colorectal adenoma Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 201000011190 diabetic macular edema Diseases 0.000 claims description 2
- 230000002497 edematous effect Effects 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 201000005264 laryngeal carcinoma Diseases 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims description 2
- 230000007135 neurotoxicity Effects 0.000 claims description 2
- 231100000228 neurotoxicity Toxicity 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 210000004116 schwann cell Anatomy 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 0 IC1CCC(*C(CCC2)CCC2[Tl]c2cc(C3CCCCC3)nc(C3CCCCC3)c2)CC1 Chemical compound IC1CCC(*C(CCC2)CCC2[Tl]c2cc(C3CCCCC3)nc(C3CCCCC3)c2)CC1 0.000 description 24
- 102000001253 Protein Kinase Human genes 0.000 description 6
- 108060006633 protein kinase Proteins 0.000 description 6
- 239000006166 lysate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- YXIXHDJOTPNACP-UHFFFAOYSA-N C(CC1)CC1c1cc(C(CCC2)CCC2c2nc(cccc3)c3[s]2)cc(C2CCCCC2)n1 Chemical compound C(CC1)CC1c1cc(C(CCC2)CCC2c2nc(cccc3)c3[s]2)cc(C2CCCCC2)n1 YXIXHDJOTPNACP-UHFFFAOYSA-N 0.000 description 1
- YICFWXRYVYGDMW-DUXPYHPUSA-N C/C=C/C(CCCC(N)=O)=O Chemical compound C/C=C/C(CCCC(N)=O)=O YICFWXRYVYGDMW-DUXPYHPUSA-N 0.000 description 1
- LCRBEVXSFPZHDF-DUXPYHPUSA-N C/C=C/C(CCCC(NCC(N)=O)=O)=O Chemical compound C/C=C/C(CCCC(NCC(N)=O)=O)=O LCRBEVXSFPZHDF-DUXPYHPUSA-N 0.000 description 1
- YEPNDNGRLHGWRF-UHFFFAOYSA-N CC(C)=CCC(N)=O Chemical compound CC(C)=CCC(N)=O YEPNDNGRLHGWRF-UHFFFAOYSA-N 0.000 description 1
- OCJXOPNZHPMZKV-UHFFFAOYSA-N CC(C)c(cccc1[N+]([O-])=O)c1F Chemical compound CC(C)c(cccc1[N+]([O-])=O)c1F OCJXOPNZHPMZKV-UHFFFAOYSA-N 0.000 description 1
- OSUSHJKMXVMILZ-UHFFFAOYSA-N CCC(C)CNC Chemical compound CCC(C)CNC OSUSHJKMXVMILZ-UHFFFAOYSA-N 0.000 description 1
- SEEYREPSKCQBBF-UHFFFAOYSA-N CN(C(C=C1)=O)C1=O Chemical compound CN(C(C=C1)=O)C1=O SEEYREPSKCQBBF-UHFFFAOYSA-N 0.000 description 1
- BDBRTGBOSYVGCD-UHFFFAOYSA-N C[S]=1(C)(C)=CN=[I]N=CC=1 Chemical compound C[S]=1(C)(C)=CN=[I]N=CC=1 BDBRTGBOSYVGCD-UHFFFAOYSA-N 0.000 description 1
- ZMEAHKIIWJDJFT-UHFFFAOYSA-N Cc(cc(cc1)C#N)c1F Chemical compound Cc(cc(cc1)C#N)c1F ZMEAHKIIWJDJFT-UHFFFAOYSA-N 0.000 description 1
- UHNUYEACFGAWEG-UHFFFAOYSA-N Cc(cncc1)c1F Chemical compound Cc(cncc1)c1F UHNUYEACFGAWEG-UHFFFAOYSA-N 0.000 description 1
- DZNXMHJMXLSNIR-UHFFFAOYSA-N Cc1cnccc1Cl Chemical compound Cc1cnccc1Cl DZNXMHJMXLSNIR-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KCSKCIQYNAOBNQ-YBSFLMRUSA-N biotin sulfoxide Chemical compound N1C(=O)N[C@H]2CS(=O)[C@@H](CCCCC(=O)O)[C@H]21 KCSKCIQYNAOBNQ-YBSFLMRUSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451022P | 2011-03-09 | 2011-03-09 | |
| US61/451,022 | 2011-03-09 | ||
| PCT/US2012/028293 WO2012122383A2 (en) | 2011-03-09 | 2012-03-08 | Pi3 kinase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511395A JP2014511395A (ja) | 2014-05-15 |
| JP2014511395A5 true JP2014511395A5 (cg-RX-API-DMAC7.html) | 2015-04-30 |
Family
ID=46798805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557866A Pending JP2014511395A (ja) | 2011-03-09 | 2012-03-08 | Ｐｉ３キナーゼインヒビターおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120258967A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2683243A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014511395A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103501610A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012225382B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2829558A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012122383A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2841075T3 (pl) | 2012-04-26 | 2020-09-21 | The General Hospital Corporation | Środki i sposoby leczenia i zapobiegania rogowaceniu łojotokowemu |
| MX386935B (es) | 2013-03-14 | 2025-03-04 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| TWI710558B (zh) * | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| CN104140426B (zh) * | 2013-05-07 | 2017-02-01 | 上海汇伦生命科技有限公司 | 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途 |
| WO2014186663A2 (en) * | 2013-05-17 | 2014-11-20 | The General Hospital Corporation | Methods for detecting and treating variants of seborrheic keratoses |
| CN104651368B (zh) * | 2013-11-15 | 2017-09-29 | 北京大学 | 一种核酸适配体bc15的核心序列及其类似物和应用 |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| WO2016172952A1 (zh) * | 2015-04-30 | 2016-11-03 | 江苏挪贝肽医药科技有限公司 | PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用 |
| GB201602527D0 (en) * | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| CN112189012B (zh) | 2018-04-10 | 2024-02-13 | 神经孔疗法股份有限公司 | 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物 |
| EP3806833A1 (en) * | 2018-06-15 | 2021-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity |
| LT3860998T (lt) | 2018-10-05 | 2024-06-25 | Annapurna Bio Inc. | Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| AU2021324684A1 (en) * | 2020-08-11 | 2023-04-20 | Board Of Trustees Of Michigan State University | Proteasome enhancers and uses thereof |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| TW202337433A (zh) * | 2022-02-08 | 2023-10-01 | 美商德洛斯股份有限公司 | 用於治療癌症及其他適應症之組成物及方法 |
| CN115417789B (zh) * | 2022-09-03 | 2023-08-04 | 郑州大学 | 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用 |
| CN122122158A (zh) * | 2023-08-08 | 2026-05-29 | 瑟拉斯有限公司 | 用于治疗癌症和其他适应症的稠合吡啶 |
| WO2026076002A1 (en) * | 2024-10-01 | 2026-04-09 | Theras, Inc. | Compositions and methods for use in the treatment of cancer and other indications |
| WO2026080380A1 (en) * | 2024-10-07 | 2026-04-16 | Theras, Inc. | Compositions and methods for use in the treatment of cancer and other indications |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200510383A (en) * | 2003-07-16 | 2005-03-16 | Neurogen Corp | Biaryl piperazinyl-pyridine analogues |
| CA2531619A1 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| WO2006071538A2 (en) * | 2004-12-13 | 2006-07-06 | Neurogen Corporation | Substituted biaryl analogues |
| CA2671845C (en) * | 2006-12-07 | 2015-03-24 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| CA2675558A1 (en) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| WO2009066084A1 (en) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| US20090149458A1 (en) * | 2007-11-27 | 2009-06-11 | Wyeth | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS |
| US7820665B2 (en) * | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| DE102009015255A1 (de) * | 2009-04-01 | 2010-10-14 | GM Global Technology Operations, Inc., Detroit | Tankklappenmodul |
| ES2439793T3 (es) * | 2009-04-17 | 2014-01-24 | Wyeth Llc | Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| KR20120063515A (ko) * | 2009-09-09 | 2012-06-15 | 아빌라 테라퓨틱스, 인크. | Ｐｉ３ 키나제 억제제 및 이들의 용도 |
| WO2013033901A1 (en) * | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
-
2012
- 2012-03-08 CN CN201280021536.0A patent/CN103501610A/zh active Pending
- 2012-03-08 AU AU2012225382A patent/AU2012225382B2/en not_active Expired - Fee Related
- 2012-03-08 US US13/414,918 patent/US20120258967A1/en not_active Abandoned
- 2012-03-08 CA CA2829558A patent/CA2829558A1/en not_active Abandoned
- 2012-03-08 WO PCT/US2012/028293 patent/WO2012122383A2/en not_active Ceased
- 2012-03-08 EP EP12755552.2A patent/EP2683243A4/en not_active Withdrawn
- 2012-03-08 JP JP2013557866A patent/JP2014511395A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504325A5 (cg-RX-API-DMAC7.html) | ||
| AU2020271855B2 (en) | Heterocyclic compounds as kinase inhibitors for therapeutic uses | |
| KR102333718B1 (ko) | 항암 및 항-증식 활성을 나타내는 n-아실-n'-(피리딘-2-일) 우레아 및 유사체 | |
| JP6445701B2 (ja) | Ｅｒｋ阻害剤としてのチエノ［２，３−ｃ］ピロール−４−オン誘導体 | |
| JP5188988B2 (ja) | ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 | |
| CN109776445B (zh) | 苯并噁二唑类化合物及其制备方法和医药用途 | |
| AU2018338098B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| IL270363B1 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| JP7728287B2 (ja) | Ｃｄｋ６／ｄｙｒｋ２二重標的阻害剤およびその製造方法と応用 | |
| BR112016003247B1 (pt) | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso | |
| BRPI0614578A2 (pt) | composto, composição farmacêutica como inibidores de proteìna cinases, bem como seu método e uso | |
| KR20260042557A (ko) | 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 | |
| AR060633A1 (es) | Derivados de furo[3, 2-d]pirimidina, furo[2, 3-d]pirimidina, tieno[3, 2-d]pirimidina y tieno[2, 3-d]pirimidina, metodos para su preparacion, composiciones farmaceuticas y obtencion de las mismas, el uso de estos derivados en la fabricacion de medicamentos, kits y productos para el tratamiento de enf | |
| BRPI0614804A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| KR102582752B1 (ko) | 단백질 키나아제 억제제 | |
| WO2020007275A1 (zh) | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2014520108A5 (cg-RX-API-DMAC7.html) | ||
| KR102372288B1 (ko) | 단백질 키나아제 억제제로서의 아미노티아졸 화합물 | |
| AU2021310000A1 (en) | Pyrazolopyrimidine compound used as ATR kinase inhibitor | |
| ES2985416T3 (es) | Nuevos compuestos potentes y selectivos como moduladores del receptor de serotonina 1B | |
| JP2020536113A (ja) | 上皮成長因子受容体阻害剤 | |
| CN106414448B (zh) | 可用作s100-抑制剂的新型化合物 | |
| CA3014853A1 (en) | Substituted aminopyridine compound, preparation, and use as a fibroblast growth factor receptor kinase inhibitor | |
| CN104093719A (zh) | 作为酪氨酸激酶抑制剂的三唑并吡啶衍生物 | |
| JP2021518855A (ja) | Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体 |